Pulmonary and Nasal drug delivery are promising delivery routes for a range of different therapeutic application areas. This implies that DirectHaler™ Pulmonary and DirectHaler™ Nasal may have each their or even shared application areas - as both the nasal and pulmonary routes are applicable for systemic delivery.

Among the expected application areas are: Respiratory diseases (Asthma, COPD, Rhinitis), Pain management, Diabetes (Insulin delivery), Vaccines, Osteoporosis, Nicotine therapy, Erectile Dysfunction and Sleep disorders.

DirectHaler™ Pulmonary license availability
Patent protection at least until 2015.

• Non-respiratory systemic applications are available for licensing.
• Exclusive world-wide license for Respiratory Lung Diseases is acquired by Zambon Group SpA.

DirectHaler™ Nasal license availability
Patent protection at least until 2018.

• All applications (including respiratory diseases) are available for licensing.

We invite you to take contact to Dr. Troels Keldmann, for a dialogue on license availability.

Partnership
Partnering with Direct-Haler A/S will give you access to both our innovative, easy-to-use, world-wide patented technologies and our competence network. We at Direct-Haler A/S can help you open new and unexploited opportunities:

• Differentiate and add value to your existing product line - and extend the product lifecycle by the world-wide patent protection of the DirectHaler technologies.
• Provide novel but proven delivery concept for your new product.
• Enable you to manage your own high-speed DirectHaler™ manufacturing line, including filling and packing of the finished pulmonary/nasal product.
• Customization of the DirectHaler™ Technologies for your specific therapeutic application and for your specific patient population.

Our approach
We acknowledge that deciding for a drug delivery system is an important and long term decision, requiring both scientific and commercial evaluations. We prefer to be involved in the dialogue at the very early point in the process of selecting delivery system. We can, together with our network, perform feasibility tests of the combination device/formulation. Further, we will be able to supply high numbers of devices for your clinical trials.

Every project for inhaled delivery has its own specific technical requirements, and therefore we believe in defining the needs of each project, before assigning the needed expertise from our network of collaborators in any relevant field of competence.

Welcoming new opportunities
Direct-Haler A/S has a flexible outlook on the development of the companys business, and in how our technology can be fully exploited and commercialized. We are looking for business partnerships both concerning commercialization (route to market) and for accessing complementary technology to the DirectHaler™ technologies.

We invite you to take contact to Dr. Troels Keldmann, for a dialogue on opportunities for collaboration.

DIRECT-HALER A/S
Symbion Science Park           
Fruebjergvej 3
DK-2100 Copenhagen
Denmark

Phone: +45 39 17 96 96
Fax:     +45 39 17 96 90
Email:  keldmann@directhaler.com